Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.

By D. Bergqvist, G. Agnelli, A. Cohen, A. Eldor, P. Nilsson, Anne Le Moigne-Amrani, F. Dietrich-Neto. New England Journal of Medicine, 2002

642 citations recorded by the source corpus.

Subfields: Hepatology, Internal Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/74b619b1135fce69977d2ac6fcb2707931a0a06d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. O. Ljungqvist
2. J. Nygren

Citations in the corpus

• Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update (2019, methodology): “70 71 The randomized controlled trial ENOXACAN II demonstrated a 60% reduction in the VTE rate in patients undergoing surgery for cancer who received 28 days of low molecular weight heparin compared with those who received only 10 days of low molecular weight heparin.(72) Addition-”